| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2703985 | Journal of Stroke and Cerebrovascular Diseases | 2014 | 5 Pages |
Abstract
These data suggest that the proportion of poor/intermediate clopidogrel metabolizers in cerebrovascular patients is comparable to cardiovascular studies and these patients may have an increased risk of recurrent cerebrovascular events. Routine CYP2C19 testing may be warranted.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Clinical Neurology
Authors
Ilana MD, Nobl MD, PhD, Victor MD, Jack MD, Charlene MD, Christine MD, David MD, FAHA, FAAN,